What RAD 140 dose do human studies report?

Doses and schedules in human studies
TrialDose and schedulePeopleLength
LoRusso and colleagues (2022), first-in-human trial50 mg, 100 mg or 150 mg once daily1Twenty-two women in the paper: 6, 13 and 3 in the three arms; the registry entry lists 202Not stated
Wagener and colleagues, micro-dose1, 10 or 50 μg, as a single dose or a multi-dose course3Thirty healthy men, five per groupOne dose, or five doses on five consecutive days

No label or regulator-set dose turned up for RAD 140; the phase 1 trial by LoRusso and colleagues (2022), in twenty-two postmenopausal women with metastatic breast cancer, gave 50 mg, 100 mg or 150 mg once daily, with 100 mg/day the maximum tolerated dose.1

Doses and schedules in human studies

The table is set at the top of the page

The phase 1 trial was a 3 + 3 dose escalation in postmenopausal women with ER+/HER2- metastatic breast cancer, not healthy people or people building muscle.1 The paper describes RAD140 as an oral agent, the registry entry says its drug was supplied as capsules, and Part A assigned patients sequentially to escalating doses.12 The registry entry sets the dose-limiting toxicity window as the first 28 days of treatment, but the length of treatment per patient is not stated in the trial paper's summary.2 In the micro-dose study, concentrations built up when doses were 24 hours apart.3 The searches found no cycle length from any trial or regulator, and the only stepping is the 3 + 3 escalation across the three arms.1

Regulatory status and safety warnings

The FDA says SARMs are not FDA approved and cannot be legally marketed in the US as a drug or dietary supplement.4 Sport Integrity Australia says SARMs are not approved for human use in any capacity and that there is no standardisation of dosages.5 An FDA warning letter says life-threatening reactions including liver toxicity have occurred with SARM products, and that they may raise heart attack and stroke risk.6 In the phase 1 trial, grade 3/4 treatment-emergent adverse events occurred in 16 (72.7%) of the twenty-two women across the three doses, and the most frequent event was elevated AST (59.1%).1

Amounts in case reports and product labels

Outside trials, the amounts come from self-reported use in single case reports. One man took a product labelled 10 mg RAD-140 per capsule, two capsules a day, for 4 weeks.7 He then took a product labelled 7.5 mg RAD-140 and 5 mg LGD-4033 per capsule, two a day, for 3 weeks.7 Another man took up to 15 mg a day for 5 weeks, and a third took a product labelled 10 mg at a total of 20 mg a day for three months.89 All of these amounts are below the 50 mg lowest arm of the phase 1 trial.1 An analysis of 16 supplements bought online found no testolone reliably identified in the 4 samples declared to contain it, and its authors say such supplements may not contain the declared SARMs at all or may contain incorrect amounts.10

Liquids, mL and storage

Sources give no concentration for a human RAD 140 liquid, so no mg to mL conversion is printed. The micro-dose study spiked a 1 mg/mL ethanol stock into 120 mL of drinking yoghurt, a research preparation rather than a label instruction.3 The authors of one case report say a liquid dropper form likely made an accurate dose harder and led to unintentional toxic dosing.11 Storage conditions, shelf life and stability data, before or after mixing, did not turn up in the search.

Frequently asked questions

What is the half-life of RAD 140?

The phase 1 paper reports a half-life of 44.7 hours, which supported once-daily dosing.1 Milligram's app uses 60 hours as a model setting; that figure is not taken from these sources, which give 44.7 hours.1

What strengths do RAD 140 capsules come in?

Four testolone capsule products in a supplement analysis declared 5 mg or 10 mg of RAD-140 per capsule on their labels, but testolone was not reliably identified in any of the 4;10 in one case report, the products were labelled 10 mg and 7.5 mg of RAD-140 per capsule.7

References

  1. Clinical Breast Cancer. A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer. 2022. pubmed.ncbi.nlm.nih.gov
  2. ClinicalTrials.gov. NCT03088527: Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer. 2020. clinicaltrials.gov
  3. Metabolites. Human In Vivo Metabolism and Elimination Behavior of Micro-Dosed Selective Androgen Receptor Modulator RAD140 for Doping Control Purposes. 2022. pmc.ncbi.nlm.nih.gov
  4. US FDA. Social Media Posts by Influencers and Online Sellers Promote SARMs Use. fda.gov
  5. Sport Integrity Australia. RAD-140 Health Warning | Sport Integrity Australia. sportintegrity.gov.au
  6. US FDA. TITAN SARMS LLC - 719645 - 12/12/2025. fda.gov
  7. case report. Drug-Induced Liver Injury Associated With Alpha Bolic (RAD-140) and Alpha Elite (RAD-140 and LGD-4033). 2020. pmc.ncbi.nlm.nih.gov
  8. case report. RAD-140 Drug-Induced Liver Injury. 2022. pmc.ncbi.nlm.nih.gov
  9. case report. Selective Androgen Receptor Modulators Leading to Liver Injury: A Case Report. 2024. pmc.ncbi.nlm.nih.gov
  10. case report. Rapid detection of illegal selective androgen receptor modulators in unregistered supplements using a combination of selected solid-state analytical methods. 2025. pmc.ncbi.nlm.nih.gov
  11. case report. Idiosyncratic drug-induced liver injury related to use of novel selective androgen receptor modulator RAD140 (Testalone): a case report. 2023. pmc.ncbi.nlm.nih.gov